Abstract Based on a putative 'Y shape'pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group- reverse strategy. Among synthesized target compounds, 16g (IC 50= 25.73 nM) and 16i (IC 50= 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC 50= 25.43 nM) in calcium mobilization assay. Selected compounds ...